Syndax Pharmaceuticals Inc
SNDXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Syndax Pharmaceuticals Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 12 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Legato Capital Management LLC | 2026-03-31 | 41,376 | $967K | SEC filing |
| State of New Jersey Common Pension Fund D | 2026-03-31 | 27,968 | $653K | SEC filing |
| Squarepoint Ops LLC | 2026-03-31 | 181,552 | $4.24M | SEC filing |
| Larson Financial Group LLC | 2026-03-31 | 2,594 | $60.6K | SEC filing |
| PROFUND ADVISORS LLC | 2026-03-31 | 55,904 | $1.31M | SEC filing |
| HighTower Advisors, LLC | 2026-03-31 | 37,031 | $865K | SEC filing |
| Swiss National Bank | 2026-03-31 | 161,400 | $3.77M | SEC filing |
| Clearline Capital LP | 2026-03-31 | 43,413 | $1.01M | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 54,274 | $1.27M | SEC filing |
| Post Resch Tallon Group Inc. | 2026-03-31 | 12,500 | $302K | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 39,904 | $932K | SEC filing |
| SECTORAL ASSET MANAGEMENT INC | 2026-03-31 | 31,680 | $787K | SEC filing |
| HSBC HOLDINGS PLC | 2026-03-31 | 23,461 | $556K | SEC filing |
| JPL Wealth Management, LLC | 2026-03-31 | 5 | $117 | SEC filing |
| Aisling Capital Management LP | 2026-03-31 | 1,316,806 | $30.8M | SEC filing |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-03-31 | 22,545 | $567K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 4,249,836 | $99.3M | SEC filing |
| Pale Fire Capital SE | 2026-03-31 | 284,460 | $6.64M | SEC filing |
| AQR CAPITAL MANAGEMENT LLC | 2026-03-31 | 980,314 | $22.9M | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 101,492 | $2.37M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Syndax Pharmaceuticals Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-09-08 · Metzger Michael A: Larger than all 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-20 · Morrison Briggs: Larger than 60 of the 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-19 · Morrison Briggs: Larger than 65 of the 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-16 · Morrison Briggs: Larger than 63 of the 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-15 · Podlesak Dennis: Larger than 62 of the 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-15 · Morrison Briggs: Larger than 61 of the 66 other insider sales of Common Stock on file. SEC filing
- 2022-09-14 · Morrison Briggs: Larger than 64 of the 66 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-12 | Botwood Nicholas A.J. · Head of R&D, CMO | Common Stock | S — Open market or private sale | −31,235 | 18.14 | SEC filing |
| 2026-06-11 | Botwood Nicholas A.J. · Head of R&D, CMO | Common Stock | S — Open market or private sale | −34,280 | 18.00 | SEC filing |
| 2026-06-01 | Metzger Michael A · Chief Executive Officer | Common Stock | S — Open market or private sale | −6,847 | 18.99 | SEC filing |
| 2026-06-01 | Goldan Keith A. · Chief Financial Officer | Common Stock | S — Open market or private sale | −1,177 | 18.99 | SEC filing |
| 2026-02-09 | Metzger Michael A · Chief Executive Officer | Common Stock | S — Open market or private sale | −17,159 | 21.03 | SEC filing |
| 2026-02-09 | Goldan Keith A. · Chief Financial Officer | Common Stock | S — Open market or private sale | −3,410 | 21.03 | SEC filing |
| 2026-02-06 | Metzger Michael A · Chief Executive Officer | Common Stock | S — Open market or private sale | −7,412 | 20.62 | SEC filing |
| 2026-02-06 | Goldan Keith A. · Chief Financial Officer | Common Stock | S — Open market or private sale | −2,082 | 20.62 | SEC filing |
Showing 8 of 15 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-12 | Botwood Nicholas A.J. · Head of R&D, CMO | Common Stock | M — Exercise or conversion of derivative security | +31,235 | SEC filing |
| 2026-06-12 | Botwood Nicholas A.J. · Head of R&D, CMO | Stock options (Right to buy) | M — Exercise or conversion of derivative security | +31,235 | SEC filing |
| 2026-06-11 | Botwood Nicholas A.J. · Head of R&D, CMO | Common Stock | M — Exercise or conversion of derivative security | +22,515 | SEC filing |
| 2026-06-11 | Botwood Nicholas A.J. · Head of R&D, CMO | Stock options (Right to buy) | M — Exercise or conversion of derivative security | +22,515 | SEC filing |
| 2026-02-04 | Jarrett Jennifer · Director | Common Stock | A — Grant, award, or other acquisition | +24,000 | SEC filing |
| 2026-02-04 | Botwood Nicholas A.J. · Head of R&D, CMO | Common Stock | A — Grant, award, or other acquisition | +24,000 | SEC filing |
| 2026-02-04 | Metzger Michael A · Chief Executive Officer | Common Stock | A — Grant, award, or other acquisition | +144,600 | SEC filing |
| 2026-02-04 | Goldan Keith A. · Chief Financial Officer | Stock Options (Right to buy) | A — Grant, award, or other acquisition | +118,000 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-01-30 | Goldan Keith A. · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | +1,219 | SEC filing |
| 2025-07-31 | Goldan Keith A. · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | +1,226 | SEC filing |
| 2024-01-31 | Goldan Keith A. · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | +1,183 | SEC filing |
| 2023-07-31 | Goldan Keith A. · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | +862 | SEC filing |
| 2023-01-31 | Ordentlich Peter · Chief Scientific Officer | Common Stock | J — Other acquisition or disposition | +69 | SEC filing |
| 2022-07-29 | Ordentlich Peter · Chief Scientific Officer | Common Stock | J — Other acquisition or disposition | +265 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.